BioSpace

Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work

Eli Lilly's business development team has inked 14 buyouts this year so far, with Calytrix Bio tucking into the pharma’s oncology pipeline.

By BioSpace

1 min read
Lilly’s early-stage M&A quest finds $1.5B deal for Calytrix’s blood cancer work
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights